VIM and lung adenocarcinoma: Investigation of a full-body vimentin knock-out (VIM−/−) in a described mouse model of lung adenocarcinoma carrying the LSL-KrasG12D and Lkb1fl/fl driver mutations revealed that loss of vimentin had no effect on the development of primary tumors.